Ignite Creation Date:
2025-12-24 @ 5:08 PM
Ignite Modification Date:
2026-01-29 @ 11:59 PM
Study NCT ID:
NCT03068650
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2017-10-18
First Post:
2017-02-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut
Sponsor:
Celldex Therapeutics
Organization:
Study Overview
Official Title:
Expanded Access (Compassionate Use) Treatment Protocol Rindopepimut (CDX-110)
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CDX-110
Brief Summary:
Celldex endeavors to make investigational products available to patients with life-threatening diseases who have exhausted other treatment options and where there is a reasonable expectation of benefit over risk. Requests for expanded access to rindopepimut in patients with EGFRvlll expressing recurrent glioblastoma will be considered.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: